Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Sign up Log in

MorphoSys AG Investor Presentation 2011

Jan 12, 2011

291_ip_2011-01-12_573638cd-19b6-4a9f-bf2b-036d4217489f.pdf

Investor Presentation

Open in viewer

Opens in your device viewer

{# SEO P0-1: filing HTML is rendered server-side so Googlebot sees the full text without executing JS or following an iframe to a Disallow'd CDN path. The content has already been sanitized through filings.seo.sanitize_filing_html. #}

Compyp an U date

29th Annual J.P. Morgan Healthcare Conference – January 2011

This presentation includes forward forward-looking statements. looking

Actual results could differ materially from those included in the forward-looking statements due to various risk factors and uncertainties including changes in business, economic competitive conditions regulatory reforms foreign exchange rate fluctuations and the conditions, reforms, the availability of financing.

These and other risks and uncertainties are detailed in the Company's Annual Report.

C
o
m
p
a
n
y		 A
i
d
d
t
t
i
b
d
"
n
n
e
p
e
n
e
n
a
n
o
y
c
o
m
p
a
n
y
/
/
G
G
&
S
M
t
i
i
d
i
t
h
i
t
i
U
K
U
"
a
r
n
s
r
e
e
e
r
r
m
m
a
a
n
n
y
y
w
s
e
s
n
,
F
k
f
S
k
E
h
T
D
A
X
t
t
"
r
a
n
r
o
c
c
a
n
g
e
e
c
u
x
–
B
i
u
s
n
e
s
s		 T
T
h
h
i
i
i
i
b
b
d
d
i
i
t
t
t
t
"
e
r
a
p
e
c
a
n
o
e
s
u
&
(
S
)
R
h
d
i
t
i
t
i
b
d
i
A
b
D
t
"
e
s
e
a
r
c
a
g
n
o
s
c
a
n
o
e
s
e
r
o
e
c
T
h
l
e
c
n
o
o
g
y		 L
d
i
i
H
C
A
L
l
f
t
t
"
e
a
n
g
p
r
o
p
r
e
a
r
p
a
o
r
m
y
u
,
f
S
N
t
h
l
l
i
i
i
t
i
"
e
w
e
c
n
o
o
g
y
r
o
m
o
n
n
g
a
c
q
u
s
o
n
P
i
l
i
p
e
n
e		 O
0
h
i
i
b
d
7
t
t
t
"
e
r
e
r
a
p
e
c
a
n
o
p
r
o
g
r
a
m
s
v
u
y
S
t
l
l
i
i
t
h
h
i
"
r
o
n
g
a
a
n
c
e
s
w
p
a
r
m
a
c
o
m
p
a
n
e
s
i
i
F
l
n
a
n
c
a
s		 S
i
b
l
f
i
b
i
l
i
f
d
i
R
&
D
t
t
t
t
"
s
a
n
a
e
p
r
o
a
n
s
p
r
o
p
r
e
a
r
u
y
u
y
\$
1
0
1
b
t
t
i
l
l
i
i
t
h
N
t
i
"
-y
e
a
r,
n
s
r
a
e
g
c
a
a
n
c
e
w
o
v
a
r
s
\$
\$
C
C
h
h
b
b
l
l
i
i
f
f
1
1
7
7
0
0
"
a
s
a
a
n
c
e
n
e
c
e
s
s
o
m
x

PROPRIETARY DEVELOPMENT

Own programs taken by MorphoSys to clinical proof-of-concept Lucrative potential upside

PARTNERED DISCOVERY

  • Multiple therapeutic antibody products based on MorphoSys's technology
  • Generate strong flow of milestones & royalties y

AbD SEROTEC

  • p p yp Growing roster of diagnostic partnerships g gp p developing novel tests
  • Research antibody catalogue business

INNOVATIVE, PROPRIETARY ANTIBODY TECHNOLOGY

  • Commitment to delivering superior antibodies
  • Next generation MAbs to be more efficacious, able to hit new targets and lower cost

October 2010:

MorphoSys acquires Sloning BioTechnology for access to Slonomics

Slonomics:

  • Enzy a c ge e sy es s matic gene synthesis
  • Enables generation of protein libraries
  • With unprecedented speed
  • With l t t l itiWith complete control over composition
  • At low cost

Powerful technology for protein discovery & optimization

December 2010:

Slonomics agreement with Pfizer provides p immediate payback of Sloning acquisition and foreshadows commercial potential

A Uniq gp , ue Platform for Generating Optimized, Fully Human Antibodies

Higher Probabilities of Success & Faster Development

Today

Expectations:

  • Shorten time to antibody drug candidate by 30%
  • Increase proportion of programs reaching clinic to 50%

Broadest Antibody Pipeline in the Industry: yp y 77 Programs Ongoing

N
a
m
e		 P
/
M
O
R
t
a
r
n
e
r		 T
t
a
r
g
e		 I
d
i
i
t
n
c
a
o
n		 D
i
s
c
o
e
ry
v		 P
l
i
i
r
e
c
n
c		 P
h
1
a
s
e		 P
h
2
a
s
e		 P
h
3
a
s
e		 M
k
t
a
r
e
M
O
R
1
0		 R
A
3 M
O
R		 G
M-
C
S
F		 S
M
B
H
Q
8
8
0		 No
t
is
va
r		 D
K
K-
1		 Ca
nc
er
C
an
ce
r
C
N
T
O
8
8
8		 Ce
to
n
co
r		 M
C
P-
1		 I
P
F
d.
n.		 No
t
is
va
r		 d.
n.		 d.
n.
Ga
te
b
n
ne
ru
ma		 Ro
he
c		 Am
lo
i
d-
β
y		 A
D
O
2
0
8
M
R		 M
O
R		 C
D
1
9		 C
L
L
C
N
T
O
1
9
9
5		 Ce
to
n
co
r		 d.
n.		 Ps
ias
is
or
B
A
Y
9-
4
6
2
0
7		 Ba
Sc
he
ing
er
r
y		 C
A
I
X
(
M
N
)		 Ca
nc
er
C
O
3
1
N
T
5
7		 Ce
to
n
co
r		 d.
n.		 As
t
hm
a
d.
n.		 No
t
is
va
r		 d.
n.		 Mu
los
ke
le
ta
l
sc
u
d.
n.		 No
t
is
va
r		 d.
n.		 Op
h
t
ha
lm
log
o
y
d.
n.		 Ce
to
n
co
r		 d.
n.		 In
f
lam
t
ion
/
ma
Au
to
im
mu
ne
3
Pr
og
ra
ms		 3
Pa
tn
r
er
s		 d.
n.		 In
f
lam
ion
/
t
ma
Ca
nc
er		 *
In
lu
d
M
O
R
2
0
2		 M
O
R		 C
D
3
8		 Mu
l
ip
le
My
lom
t
e
a		 c
e
s
in
f
la
m
m
a		 c
a
nc
e
r,
to
ry
,
2
0
Pr
og
ra
ms		 Pa
tn
d
r
er
e		 Va
iou
r
s		 Va
Va
iou
iou
*
r
r
s
s		 to
im
au
m
in
fe
io
t
c
u		 ne
u
,
s,
3
2
Pr
og
ra
ms		 Pa
tn
d
r
er
e		 Va
iou
r
s		 *
Va
iou
r
s		 lo
m
u
s
cu
l n
tra
c
e
n		 ke
le
l
&
ta
s
e
rv
ou
s
5
Pr
og
ra
ms		 O
M
R		 d.
n.		 In
f
lam
ion
/
t
ma
Ca
nc
er		 te
d
sy
s
m		 is
e
a
s
e
s
2
Pr
og
ra
ms		 M
O
R
/
N
O
V		 d.
n.		 In
f
lam
t
ion
ma		 d
d.
t
n
n.
no
–		 d
is
lo
d
c
s
e

Corporate Technology Pipeline AbD Serotec

MOR103A Novel Anti-Inflammatory Antibody

The Target

  • GM-CSF which plays a central role in activating granulocytes and CSF, macrophages
  • Extensive evidence implicating GM-CSF in the inflammatory cascade

The Drug

  • A HuCAL IgG1 antibody that neutralizes human GM-CSF
  • High potency due to very high target affinity (KD = 0.4 pM)
  • Subcutaneous PK study in healthy volunteers planned for 2011 volunteers

Intellectual Property

  • Exclusive license to a US patent covering antibodies against GM-CSF for the treatment of chronic inflammatory conditions
  • Patent filings on antibody

Corporate Technology Pipeline AbD Serotec Page 10

© MorphoSys AG MorphoSys

MOR103Clinical Development

In Rheumatoid Arthritis

  • European phase 1b/2a trial ongoing to assess safety signs of efficacy and safety, immunogenicity of MOR103 in patients with active RA
  • 135 patients with active RA, randomized, double-blind, placebo controlled
  • Four ascending doses i.v. 0.3, 1.0 and 1.5 mg/kg or placebo with stable regimen of concomitant RA therapy
  • Objectives:
  • Primary objectives: Adverse event rate and safety profile
  • Secondary objectives: DAS28, ACR & EULAR28, cytokines, MRI (synovitis & bone edema), PK, immunogenicity & patient-reported outcomes up to 16 wks
  • Final phase 1b/2a RA data expected in H1 2012

In Multiple Sclerosis

Phase 1b safety study in MS patients being prepared

MOR208A Novel Anti-Cancer Antibody

The Target

CD19 a pan B-cell marker

The Drug

  • Humanized, affinity optimized anti-CD19 antibody, comprising a proprietary modification that enhances effector cell recruitment
  • E l i li f X s Exclusive license from Xencor

Selected Pre-clinical Observations

  • Enhanced affinity for Fc receptor leads to rapid and sustained B-cell depletion
  • H Higher ADCC than both Rituxan & Campath against all lymphoma & leukemia cell lines tested (see selected data in figure) 0.01 0.1 10 0 100 rituximab (CD20)

MOR208Clinical Development

Clinical Trial Design

  • Multi-centre open centre, open-label multi label, multi-dose single dose, single-arm phase 1 dose arm 1, dose-escalation escalation study in USA
  • Patients with chronic lymphocytic leukemia, who have not responded to or h b f t t i th ihave become refractory to previous therapies
  • Objectives:
  • Primary objectives: Investigate maximum tolerated dose safety and tolerated dose, tolerability, pharmacokinetics and immunogenicity
  • Secondary objectives: Assess preliminary anti-tumor activity
  • Xencor funds phase 1 trial from \$13 m up-front payment
  • Final data expected in 2012

MOR202A Novel Antibody for Multiple Myeloma

The Target

CD38 a key target present on the vast majority of multiple myeloma cells CD38, a present of myeloma

The Drug

A high affinity, fully human HuCAL antibody

Clinical Trial Design and Development Timeline

  • Multicentre, open-label, dose-escalation study (EU)
  • Patients with relapsed/refractory multiple myeloma; failure of at least 2 prior relapsed/refractory myeloma; of therapies
  • Objectives: Investigate maximum tolerated dose, safety and tolerability, pharmacokinetics and immunogenicity; assessment of preliminary activity
  • Final data expected in 2012

Partnered Programs Phase 2 Clinical Development

P
&
P
t
a
r
n
e
r
r
o
g
r
a
m		 i
D
s
e
a
s
e		 S
t
t
a
s
u
N
t
i
o
v
a
r
s
Q
8
8
0
B
H		 O
t
l
t
i
b
s
e
o
y
c
o
n
e
d
i
s
e
a
s
e		 H
C
A
L
i
b
d
i
D
K
K
1
t
t
t
"
a
n
o
a
r
g
e
n
g
u
y
-
C
l
i
i
l
t
i
l
i
l
t
i
l
l
t
i
t
"
n
c
a
r
a
s
n
m
u
p
e
m
y
e
o
m
a
p
a
e
n
s
E
l
d
h
i
l
i
f
b
f
i
t
t
t
t
"
a
r
y
a
a
s
o
w
s
m
u
a
o
n
o
o
n
e
o
r
m
a
o
n
N
i
t
o
a
r
s
v
d
d
n
n		 d
n		 J
2
0
0
9
S
f
h
1
/
2
t
t
"
n
e
a
r
o
p
a
s
e
u
:
C
f
f
l
i
i
l
t
h
i
d
"
n
c
a
p
r
o
o
o
c
o
n
c
e
p
a
c
e
v
e
C
O
h
B
i
h
t
t
t
e
n
o
c
o
r
r
o
o
e
c
C
N
T
O
8
8
8		 O
l
&
n
c
o
o
g
y
i
l
m
m
n
o
o
g
u
y		 C
C
H
A
L
t
i
b
d
t
t
i
M
P
1
"
u
a
n
o
y
a
r
g
e
n
g
-
M
M
C
C
P
P
1
1
l
h
h
d
t
t
t
t
t
"
r
e
g
u
a
e
s
p
r
o
s
a
e
c
a
n
c
e
r
g
g
r
r
o
o
w
w
a
n
-
i
t
t
m
e
a
s
a
s
s
2
l
t
i
l
d
1
I
P
F
t
i
l
i
"
o
n
c
o
o
g
y
r
a
s
a
n
r
a
o
n
g
o
n
g
R
h
o
c
e
G
b
t
a
n
e
n
e
r
m
a
u		 's
A
l
h
i
z
e
m
e
r
d
i
s
e
a
s
e		 β
H
H
C
C
A
A
L
L
t
t
i
i
b
b
d
d
t
t
t
t
i
i
l
l
i
i
d
d
"
u
a
n
o
y
a
r
g
e
n
g
a
m
y
o
-
β
f
A
l
i
d
i
l
i
t
d
l
t
i
A
D
"
m
y
o
m
p
c
a
e
a
s
c
a
u
s
a
a
c
o
r
n
-
P
h
2
d
i
i
i
h
d
l
A
D
i
i
i
d
t
t
t
t
t
t
"
a
s
e
s
n
p
a
e
n
s
p
r
o
r
o
m
a
n
a
e
u
y
w
Q
i
i
4
2
0
1
0
n
C
t
T
h
l
e
c
n
o
o
o
r
p
o
r
a
e		 P
i
l
i
g
p
e
n
e
y		 S
A
b
D
t
e
r
o
e
c
©
Mo
Mo
ho
ho
Sy
Sy
A
G
Pa
1
4
rp
rp
s
s
g
e

Partnered Programs Phase 1 Clinical Development

P
&
P
t
a
r
n
e
r
r
o
g
r
a
m		 D
i
s
e
a
s
e		 S
t
t
a
u
s
C
O
h
B
i
h
t
t
t
e
n
o
c
o
r
r
o
o
e
c
C
O
N
T
1
9
5
9		 P
i
i
s
o
r
a
s
s		 J
2
0
0
9
S
f
h
1
t
t
"
n
e
a
r
o
p
a
s
e
u
:
S
Q
t
d
l
t
d
i
4
2
0
1
0
"
u
y
c
o
m
p
e
e
n
B
H
l
t
h
a
y
e
r
e
a
c
a
r
e
9-
6
2
0
B
A
Y
7
4		 O
l
n
c
o
o
g
y		 O
S
f
t
b
2
0
0
9
t
t
h
1
t
i
l
"
c
o
e
r
:
a
r
o
p
a
s
e
r
a
C
A
t
i
b
d
d
j
t
t
t
i
A
I
X
"
n
o
y
r
u
g
c
o
n
u
g
a
e
a
r
g
e
n
g
-
C
O
t
t
h
B
i
t
h
e
n
o
c
o
r
r
o
o
e
c
C
N
T
O
3
1
5
7		 A
t
h
s
m
a		 2
0
1
0
S
f
1
J
t
t
h
"
u
n
e
:
a
r
o
p
a
s
e
N
t
i
o
v
a
r
s
d
n		 M
l
k
l
t
l
u
s
c
u
o
s
e
e
a
d
i
s
e
a
s
e
s		 J
l
2
0
1
0
S
f
h
1
t
t
"
a
r
o
p
a
s
e
u
y
:
N
i
t
o
v
a
r
s
d
n		 O
h
h
l
l
t
p
a
m
o
o
g
y		 A
2
0
1
0
S
f
h
1
t
t
t
"
g
s
a
r
o
p
a
s
e
u
u
:
V
i
a
r
o
s
u		 V
i
a
r
o
s
u		 F
d
d
i
i
l
I
N
D
/
C
T
A
t
"
o
r
a
o
n
a
s
s
u
A
A
d
d
i
D
b
2
0
1
0
"
n
n
n
n
o
o
u
n
n
c
c
e
e
n
e
c
e
m
e
r

A Rapy g p idly Growing Clinical Pipeline

Number of Partnered & Proprietary Programs in Clinical Trials at Year-end

© MorphoSys AG MorphoSys Page 16

Current Pipeline Projected HuCAL Drugs on the Market

Source: MorphoSys internal statistics & Tufts Centre for the Study of Drug Development

AbD Serotec Comp p lements Therapeutic Segment of the Business

Antibodies for research and diagnostic markets Cash-generative since 2007 Marketgenerative Diagnostic Antibodies Using proprietary technologies to deliver superior antibodies for diagnostic uses Future upside via royalties P t ti l i ith th ti id f b i\$ 7bn Potential synergies with therapeutic side of business Research Antibodies Catalogue comprising 15,000+ products Custom antibody generation using HuCAL \$2bn Stable and recurring cash flows

Technology g pp Offers Exciting Growth Opportunities in Diagnostics

AbD Serotec is working with over 20 diagnostics companies

A
l
i
i
t
p
p
c
a
o
n		 T
h
l
F
t
e
c
n
o
o
g
e
a
r
e
y
u
P
l
d
t
t
o
o
r
s
e
r
e
a
r
g
e
s
y
v		 H
C
A
L
i
d
i
b
d
i
h
d
i
i
l
h
f
i
l
t
t
t
p
r
o
e
s
a
n
o
e
s
e
r
e
r
a
o
n
a
a
p
p
r
o
a
c
e
s
a
u
v
w
N
b
i
k
e
w
o
m
a
r
e
r
s		 C
f
f
&
H
A
L
b
t
i
b
l
l
t
i
i
t
i
t
i
i
t
u
o
e
r
s
e
s
p
o
s
s
e
s
e
e
c
v
y
s
e
n
s
v
y
C
l
i
i
l
i
t
i
n
c
a
m
o
n
o
r
n
g		 C
H
A
L
i
l
l-
i
t
d
t
k
i
t
i-
i
d
i
t
i
t
i
b
d
i
ƒ
u
s
v
e
r
y
w
e
s
u
e
o
m
a
n
g
a
n
o
y
p
c
a
n
o
e
s
T
h
l
b
i
l
i
t
t
e
r
m
a
s
a
y		 C
f
f
I
i
t
h
d
H
A
L
k
d
t
d
t
i
t
n
v
r
o
m
e
o
u
o
e
r
s
e
y
y
a
v
a
n
a
g
g
e
s
c
o
m
p
p
a
r
e
o
n
ƒ
i
i
b
d
i
t
t
v
v
o
a
n
o
y
g
e
n
e
r
a
o
n
D
i
i
d
d
t
t
a
g
g
n
o
s
c
s
a
n
a
r
s		 C
f
f
f
H
A
L
i
d
i
d
i
i
d
i
b
i
l
i
t
t
u
o
e
r
s
p
p
r
e
c
s
e
a
n
n
e
n
e
r
e
p
p
r
o
u
c
y
y
ƒ
C
T
h
l
t
o
r
p
o
r
a
e
e
c
n
o
o
g
y		 P
i
l
i
A
b
D
S
t
p
e
n
e
e
r
o
e
c
©
Mo
Mo
ho
ho
Sy
Sy
A
G
Pa
1
9
rp
rp
s
s
g
e
G
i
d
2
0
1
0
E
u
a
n
c
e		 2
0
0
9
A
I
i
l
l
i
E
U
R
n
m
o
n		 U
d
d
i
t
p
a
e
n
D
b
e
c
e
m
e
r		 I
d
i
s
s
u
e
n
F
b
e
r
u
a
r
y
T
l
G
R
t
o
a
r
o
p
e
e
n
e
s
u
v
u		 9
1
9
4
–		 8
9
9
3
–		 8
1
0
G
O
i
P
f
i
t
t
r
o
u
p
p
e
r
a
n
g
r
o		 1
3
1
6
–		 5
9
–		 1
1
4
S
A
b
D
t
e
r
o
e
c
R
e
e
n
e
v
u		 2
1
~		 2
1
2
2
–		 1
9
4
O
i
P
f
i
M
i
t
t
p
e
r
a
n
g
r
o
a
r
g
n		 5
8
%
–		 5
8
%
–		 5
%

2010

Increase of total proprietary R&D investment to € 27 – 29 million (2009: € 19.3 million)

2011 – 2012

  • Aiming for 10% – 20% annual revenue growth
  • Maintain profitability while strengthening pipeline
Corporate

Shareholder Structure (Dec. 2009) MorphoSys (MOR GR) Key Financials

A
Z
t
s
r
a
e
n
e
c
a		 I
i
l
l
i
E
U
R
n
m
o
n		 9
M
2
0
1
0		 9
M
2
0
0
9
&
M
t
a
n
a
g
e
m
e
n
%
7		 R
e
e
n
e
s
v
u		 6
2
8		 5
7
6
S
i
B
d
5
%
u
p
e
r
v
s
o
r
y
o
a
r
2
%		 C
C
f
G
G
d
d
S
l
l
d
d
t
t
o
s
o
o
o
s
o		 5
5
5
5		 1
1
5
5
%
1
0		 &
R
D
E
x
p
e
n
s
e
s		 3
2
5		 2
7
5
S
G
&
A
E
p
e
n
s
e
s
x
,		 1
6
8		 1
5
7
%
7		 T
l
O
i
E
t
t
o
a
p
e
r
a
n
g
p
e
n
s
e
s
x		 5
4
8		 4
8
3
%
7		 O
i
P
f
i
t
t
p
e
r
a
n
g
r
o		 8
0		 9
3
4
%
4
%
%
7		 N
P
f
i
t
t
e
r
o		 7
2		 7
7
E
P
S
(
d
i
l
d
)
i
E
U
R
t
u
e
n		 0
3
2		 0
3
4

Cash, Cash Equivalents and Available-for-sale Financial Assets as of September 30, 2010:

€132.1 million

A Strategy for Substantial Value Creation

Forthcoming Events

MOR103

  • Complete enrollment in phase 1b/2a RA study pp y
  • Commence phase 1b MS study

MOR202

  • Commence phase 1 study in multiple myeloma in
  • Release pre-clinical data

MOR208

Progress report on open open-label phase 1 study in CLL label

  • New INDs
  • Clinical data expected at major conferences (ASCO, ACR, ASH…)
  • New deals

Diagnostics

Additional HuCAL-based diagnostic kits on market

PROPRIETARY DEVELOPMENT

Partnerships PARTNERED DISCOVERY

AbD SEROTEC

Thank You.

www.morphosys.com

Dr. Simon Moroney

Chief Executive Officer

Phone +49 (0)89 / 899 27-311 ( ) ( ) Fax +49 (0)89 / 899 27-5311

Dr. Claudia Gutjahr-Löser Head of Corporate Communications & IR

Phone +49 (0)89 / 899 27-122 Fax +49 (0)89 / 899 27-5122 Email [email protected]

HuCAL®, HuCAL GOLD®, HuCAL PLATINUM®, CysDisplay®, RapMAT® and AutoCAL® are registered trademarks of MorphoSys AG, arYla™ is a trademark of MorphoSys AG

More from MorphoSys AG

AGM Information 2024
Aug 27
Delisting Announcement 2024
Aug 5
AGM Information 2024
Jul 19
AGM Information 2024
Jul 19
Declaration of Voting Results & Voting Rights Announcements 2024
Jul 18
Delisting Announcement 2024
Jul 12
Legal Proceedings Report 2024
Jul 12
Report Publication Announcement 2024
Jul 5
Major Shareholding Notification 2024
Jul 2
Declaration of Voting Results & Voting Rights Announcements 2024
Jun 21
View all filings →